Pfizer sues to block Watson's Embeda copy; Celesia snaps up 60% of Brazil's Oncoprod;

@FiercePharma: From NYT, a Q&A with Novartis chief Joe Jimenez, including how he learned to welcome bad news Story | Follow @FiercePharma

> Pfizer ($PFE) sued Watson Pharmaceuticals after the generics maker asked FDA to approve its version of the pain drug Embeda, which Pfizer acquired in its deal for King Pharmaceuticals. Article

> German drug distributor Celesio bought a 60% stake in Brazil's specialty pharma wholesaler Oncoprod Group, which expects €350 million in revenue this year. Report

> India's prime minister was scheduled to meet today with three government ministers to discuss discord over proposed restrictions on foreign investment in the pharma sector. Story

> Novo Nordisk ($NVO) launched its diabetes drug Victoza in China, one of the fastest-growing diabetes markets in the world. Report

> Counterfeit drugs estimated to be a $75 billion global business. Report

> Patients in Jamaica are stockpiling their own drugs for resale, the Pharmaceutical Society of Jamaica tells Parliament. Article

> Teva Pharmaceutical Industries ($TEVA) launched an infant formula, Nutrilon, in Israel, at a 5% to 10% discount off competing brands. Story

> Milan Puskar, co-founder and former chairman of generics maker Mylan, died Friday at the age of 77. Report

Biotech News

@FierceBiotech: Mobile tech veteran Chris Toumazou pioneers DNA analysis methods. Article | Follow @FierceBiotech

@ JohnCFierce: Third Rock seeds a new approach to treating diabetes and obesity. Item | Follow @JohnCFierce

@RyanMFierce: Do niche EDC players stand a chance? This Dublin upstart has found its sweet spot with EDC for post-market apps Report | Follow @RyanMFierce

@MaureenFierce: CA passes law that removes parental consent for vaccinating kids 12 and older against STDs. More | Follow @MaureenFierce

> Pfizer stem cell study highlights sea change for a controversial field. Story

> Third Rock seeds a new approach to treating diabetes and obesity. News

Medical Device News

> MAKO aims to get hip-replacement patients back on feet faster. Piece

> Axis-Shield accepts increased Alere offer. Report

> FDA, CMS launch parallel review pilot. Item

> AngioDynamics sees net income fall in Q1. Article

> Ex-Medtronic CEO Hawkins to head Immucor. Report

Biotech IT News

> Mobile tech vet pioneers DNA analysis methods. Story

> Honoring bioinformatics pioneer on Ada Lovelace Day. More

> EDC upstart CTEP tackles Ph4 market. Article

> Software models response to H. pylori. Item

> Eric Schadt leading biotech computing charge in NYC. More

> Kansas U. nails bioinformatics faculty members for part in plagiarism. News

And Finally... Greece's economic woes are taking their toll on people's health, with HIV and drug abuse rising. Article

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.